(19)
(11) EP 2 774 935 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.06.2017 Bulletin 2017/25

(45) Mention of the grant of the patent:
19.04.2017 Bulletin 2017/16

(21) Application number: 14165977.1

(22) Date of filing: 28.10.2010
(51) International Patent Classification (IPC): 
C07K 14/47(2006.01)
A61P 25/00(2006.01)
 A61K 38/17(2006.01)
C07K 14/475(2006.01)

(54)

Improved neurturin molecules

Verbesserte Neurturinmoleküle

Molécules de neurturine améliorée

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 30.10.2009 US 256352 P

(43) Date of publication of application:
10.09.2014 Bulletin 2014/37

(62) Application number of the earlier application in accordance with Art. 76 EPC:
10827453.1 / 2493918

(73) Proprietor: NTF Therapeutics, Inc.
Chicago, IL 60615 (US)

(72) Inventors:
  • Runeberg-Roos, Pia
    Woodbury, MN Minnesota 55125 (US)
  • Bespalov, Maxim
    Woodbury, MN Minnesota 55125 (US)
  • Penn, Richard
    Woodbury, MN Minnesota 55125 (US)
  • Saarma, Mart
    Woodbury, MN Minnesota 55125 (US)

(74) Representative: Boult Wade Tennant 
Verulam Gardens 70 Gray's Inn Road
London WC1X 8BT
London WC1X 8BT (GB)


(56) References cited: : 
WO-A1-97/08196
 WO-A2-2009/059755
   
  • HAMILTON J F ET AL: "Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin", EXPERIMENTAL NEUROLOGY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 168, no. 1, 1 March 2001 (2001-03-01) , pages 155-161, XP002409643, ISSN: 0014-4886, DOI: 10.1006/EXNR.2000.7571
  • HILEMAN R E ET AL: "Glycosaminoglycan-protein interactions: Definition of consensus sites in glycosaminoglycan binding proteins", BIOESSAYS, JOHN WILEY & SONS LTD, GB, vol. 20, no. 2, 1 February 1998 (1998-02-01), pages 156-167, XP002276571, ISSN: 0265-9247, DOI: 10.1002/(SICI)1521-1878(199802)20:2<156::A ID-BIES8>3.0.CO;2-R
  • PILTONEN M ET AL: "Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons", EXPERIMENTAL NEUROLOGY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 219, no. 2, 1 October 2009 (2009-10-01), pages 499-506, XP026583797, ISSN: 0014-4886, DOI: 10.1016/J.EXPNEUROL.2009.07.002 [retrieved on 2009-07-15]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).